4D Molecular Therapeutics (NASDAQ:FDMT) Coverage Initiated at Barclays

Equities researchers at Barclays started coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research note issued on Wednesday, Marketbeat reports. The firm set an “overweight” rating and a $33.00 price target on the stock. Barclays‘s target price suggests a potential upside of 267.89% from the stock’s previous close.

A number of other research firms have also recently commented on FDMT. Morgan Stanley upgraded 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. Leerink Partners reiterated an “outperform” rating and set a $17.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, October 31st. Royal Bank Of Canada reissued an “outperform” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 7th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $26.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, December 18th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.25.

4D Molecular Therapeutics Trading Up 4.3%

Shares of FDMT opened at $8.97 on Wednesday. 4D Molecular Therapeutics has a 12-month low of $2.23 and a 12-month high of $12.34. The firm has a market capitalization of $512.46 million, a P/E ratio of -2.39 and a beta of 2.99. The firm has a 50-day moving average price of $9.01 and a 200 day moving average price of $8.25.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Monday, November 10th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.40 million. Equities research analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of FDMT. Dynamic Technology Lab Private Ltd purchased a new position in shares of 4D Molecular Therapeutics in the first quarter valued at approximately $39,000. Wexford Capital LP purchased a new stake in shares of 4D Molecular Therapeutics in the third quarter valued at about $41,000. Los Angeles Capital Management LLC purchased a new stake in shares of 4D Molecular Therapeutics during the second quarter worth about $42,000. Quadrature Capital Ltd purchased a new stake in 4D Molecular Therapeutics in the 2nd quarter worth approximately $42,000. Finally, Farther Finance Advisors LLC increased its stake in shares of 4D Molecular Therapeutics by 117.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after acquiring an additional 2,674 shares during the last quarter. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.